CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 184 enrolled
Drug / intervention
Levopront® syrup 30 mg/5 ml +1 moredrug
Likely dose
Levopront® syrup 30 mg/5 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03837938
NCT03837938Phase 3Completed

Multicenter Open-label Randomized Clinical Trial of the Efficacy and Safety of Levopront® Syrup 30 mg/5 ml in Comparison With Libexin® 100 mg Tablets in Patients With Dry Non-productive Cough Caused by Acute Upper Respiratory Infection

Dompé Farmaceutici S.p.A·interventional·Posted Feb 12, 2019·Updated Apr 16, 2024

In Brief

A Phase 3 clinical trial evaluating Levopront® syrup 30 mg/5 ml and Libexin® for Cough. Completed, enrolled 184 participants across 8 sites.

Detailed Summary

Primary objective: To assess the efficacy of Levopront® in comparison with Libexin® based on daytime cough resolution rate by Day 8. The daytime cough symptoms resolution corresponds to 0 or 1 points on the "Six-point daytime and nighttime cough assessment scale". Secondary objectives: Treatment effect assessment in terms of the following efficacy and safety parameters: * To assess the efficacy of Levopront® in comparison with Libexin® based on nighttime cough resolution rate by Day 8. * Daytime and nighttime cough symptoms resolution according to "Six-point daytime and nighttime cough assessment scale" by Day 4. * Change in severity and frequency of daytime and nighttime cough according to "Six-point daytime and nighttime cough assessment scale" on Day 4 and Day 8 from baseline on Day 1. * Cough intensity change according to the visual-analogue scale on Day 4 and Day 8 from baseline on Day 1. * Change of FEV1 on Day 8 from baseline values on Day 1. * Rate of Adverse events (AE) and Serious Adverse Events (SAE) of the various severity according to subjective complaints, laboratory test results, physical examination, vital signs and spirometry

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCough
CountriesRussia
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 12, 2019
Enrollment StartNov 9, 2016
Primary CompletionMar 6, 2018
Study CompletionJul 31, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 7.4 years ago

Interventions

Levopront® syrup 30 mg/5 mldrug

The first study drug administration was performed at the clinical site on the day of randomization; the last study drug administration was performed in the evening before Day 8 (±1).

Libexin®drug

The first study drug administration was performed at the clinical site on the day of randomization; the last study drug administration was performed in the evening before Day 8 (±1). No chewing.